Market Cap : 938.42 M | Enterprise Value : 727.88 M | PE Ratio : | PB Ratio : 4.31 |
---|
NAS:GTHX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GTHX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
G1 Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2020 was $8.13 Mil.
G1 Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Mar. 2020 ($8.62 Mil) to Jun. 2020 ($8.38 Mil) and declined from Jun. 2020 ($8.38 Mil) to Sep. 2020 ($8.13 Mil).
G1 Therapeutics's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($0.00 Mil) but then increased from Dec. 2018 ($0.00 Mil) to Dec. 2019 ($9.54 Mil).
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;No Headline